Key facts
- This page summarizes Alan H. Auerbach's Form 4 filing for PUMA BIOTECHNOLOGY, INC. (PBYI).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 11 Feb 2025, 18:51.
Alan H. Auerbach - 07 Feb 2025 Form 4 Insider Report for PUMA BIOTECHNOLOGY, INC. (PBYI)
- Reporting relationship
- President and CEO, Director, 10%+ Owner
- Issuer ticker
- PBYI
- Reported as of
- 07 Feb 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 11 Feb 2025, 18:51:06 UTC
- Prior SEC filing
- 03 Jan 2025
- Next SEC filing
- 10 Jul 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Gordon Esplin as attorney-in-fact for Alan H. Auerbach
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Filing notes and source
Key filing fact
Alan H. Auerbach filed Form 4 for PUMA BIOTECHNOLOGY, INC. (PBYI) on 11 Feb 2025.
Change
- Previous filing in this sequence was filed on 03 Jan 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PBYI
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +198,399
- Change %
- +2.8%
- Price
- $0.000000
- Shares after
- 7,228,073
- Date
- 07 Feb 2025
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
PBYI
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +274,622
- Change %
- Price
- $0.000000
- Shares after
- 274,622
- Date
- 07 Feb 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 274,622
- Exercise price
- $2.78
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Subject to Grantee's continued status as an Employee of the Company, the Restricted Stock Units ("RSUs") that shall vest with respect to one-fourth (1/4th) of the RSUs on each of July 1, 2025, January 1, 2026, July 1, 2026 and January 1, 2027, subject to acceleration in certain events.
Footnote F2
Subject to Optionee's continued status as an Employee of the Company, Options shall vest and become exercisable with respect to one-fourth (1/4th) of the Shares (as defined in the Plan) subject thereto on each of July 1, 2025, January 1, 2026, July 1, 2026 and January 1, 2027, subject to acceleration in certain events.